nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

23.12.2023 | Original Article

Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway

verfasst von: Liru Huang, Fuhong Liu, Xukai Liu, Liyan Niu, Longhua Sun, Fang Fang, Kun Ma, Ping Hu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cervical cancer (CC) ranks as the fourth most prevalent malignancy among women worldwide, necessitating effective therapeutic interventions to mitigate its detrimental impact on both physical and mental health. Parthenolide (PTL), a natural product of the sesquiterpene lactone derived from Feverfew leaves, has exhibited promising anti-tumor properties in previous studies; however, its precise effects and underlying molecular mechanisms in CC remain elusive.

Methods

In this work, we investigated the effect of PTL on the proliferation and migration of CC cells. Western blot analysis and Reverse transcription‑quantitative PCR were used for mechanistic elucidation.

Results

Our findings indicated that PTL substantially inhibited the proliferation of HeLa and SiHa CC cell lines in a dose- and time-dependent manner. Moreover, PTL significantly suppressed the migration of CC cells by down-regulating the expression of vascular endothelial growth factor (VEGF), metastasis-associated protein 1 (MTA1), and transforming growth factor-β1 (TGF-β1). Mechanistically, PTL blocked the phosphorylation of focal adhesion kinase (FAK) and glycogen synthase kinase-3β (GSK3β) induced by epidermal growth factor (EGF). Further investigations revealed that PTL suppressed the proliferation of CC cells by inhibiting the EGF-mediated phosphorylation of the FAK/GSK3β signaling pathway.

Conclusion

Taken together, the present in vitro results suggest that PTL may inhibit the proliferation and migration of CC cells through down-regulating the FAK/GSK3β signaling pathway, providing new insights for the application of PTL in the treatment of CC.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S (2023) Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 11:e197–e206. https://doi.org/10.1016/S2214-109X(22)00501-0CrossRefPubMed

Polten R, Kutle I, Hachenberg J, Klapdor R, Morgan M, Schambach A (2022) Towards novel gene and cell therapy approaches for cervical cancer. Cancers (Basel). https://doi.org/10.3390/cancers15010263CrossRefPubMed

Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27:e43. https://doi.org/10.3802/jgo.2016.27.e43CrossRefPubMedPubMedCentral

Cui G, Lanlan Z, Maoyuan Z, Yanling A, Wenhao L, Lina W, Qingsong L, Songtao L, Jinhao Z, Xiao M, Jianyuan T (2023) Targeting lipid metabolism with natural products: a novel strategy for gastrointestinal cancer therapy. Phytother Res. https://doi.org/10.1002/ptr.7735CrossRefPubMed

Guo C, Kang X, Cao F, Yang J, Xu Y, Liu X, Li Y, Ma X, Fu X (2021) Network pharmacology and molecular docking on the molecular mechanism of Luo-hua-zi-zhu (LHZZ) granule in the prevention and treatment of bowel precancerous lesions. Front Pharmacol 12:629021. https://doi.org/10.3389/fphar.2021.629021CrossRefPubMedPubMedCentral

Ghantous A, Sinjab A, Herceg Z, Darwiche N (2013) Parthenolide: from plant shoots to cancer roots. Drug Discov Today 18:894–905. https://doi.org/10.1016/j.drudis.2013.05.005CrossRefPubMed

Silvia M, Bishop RT, Giovana C, Ligan JG, Boya L, Idris IA (2019) Pharmacological Inhibition of NFκB reduces prostate cancer related osteoclastogenesis in vitro and osteolysis ex vivo. Calcified tissue Int. https://doi.org/10.1007/s00223-019-00538-9CrossRef

W L, X W, J S, Y Y, W L, J S (2017) Parthenolide suppresses pancreatic cell growth by autophagy-mediated apoptosis. OncoTargets and Therapy Volume 10. https://doi.org/10.2147/OTT.S117250

10.

Yang C, Yang QO, Kong Q-J, Yuan W, Yang Y-PO (2016) Parthenolide induces reactive oxygen species-mediated autophagic cell death in human osteosarcoma cells. Cell Physiol Biochem. https://doi.org/10.1159/000452532CrossRefPubMed

11.

Liu D, Han Y, Liu L, Ren X, Zhang H, Fan S, Qin T, Li L (2021) Parthenolide inhibits the tumor characteristics of renal cell carcinoma. Int J Oncol 58:100–110. https://doi.org/10.3892/ijo.2020.5148CrossRefPubMed

12.

Al-Fatlawi AA, Al-Fatlawi AA, Irshad M, Rahisuddin AA (2015) Effect of parthenolide on growth and apoptosis regulatory genes of human cancer cell lines. Pharm Biol 53:104–109. https://doi.org/10.3109/13880209.2014.911919CrossRefPubMed

13.

Li X, Huang R, Li M, Zhu Z, Chen Z, Cui L, Luo H, Luo L (2020) Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor. Cancer Cell Int 20:561. https://doi.org/10.1186/s12935-020-01658-1CrossRefPubMedPubMedCentral

14.

Tian B, Xiao Y, Ma J, Ou W, Wang H, Wu J, Tang J, Zhang B, Liao X, Yang D, Wu Z, Li X, Zhou Y, Su M, Wang W (2020) Parthenolide inhibits angiogenesis in esophageal squamous cell carcinoma through suppression of VEGF. Onco Targets Ther 13:7447–7458. https://doi.org/10.2147/OTT.S256291CrossRefPubMedPubMedCentral

15.

Morel KL, Ormsby RJ, Bezak E, Sweeney CJ, Sykes PJ (2017) Parthenolide selectively sensitizes prostate tumor tissue to radiotherapy while protecting healthy tissues in vivo. Radiat Res 187:501–512. https://doi.org/10.1667/RR14710.1ADSCrossRefPubMed

16.

Jeyamohan S, Moorthy RK, Kannan MK, Arockiam AJ (2016) Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer. Biotechnol Lett 38:1251–1260. https://doi.org/10.1007/s10529-016-2102-7CrossRefPubMed

17.

Zeng F, Harris RC (2014) Epidermal growth factor, from gene organization to bedside. Semin Cell Dev Biol 28:2–11. https://doi.org/10.1016/j.semcdb.2014.01.011CrossRefPubMed

18.

Thomas R, Weihua Z (2019) Rethink of EGFR in cancer with its kinase independent function on board. Front Oncol 9:800. https://doi.org/10.3389/fonc.2019.00800CrossRefPubMedPubMedCentral

19.

Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK (2013) Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med 10:192–205. https://doi.org/10.7497/j.issn.2095-3941.2013.04.003CrossRefPubMedPubMedCentral

20.

Saloni R, Sayalee S, M MS, (2022) The story of EGFR: from signaling pathways to a potent anticancer target. Fut Med Chem. https://doi.org/10.4155/fmc-2021-0343CrossRef

21.

Siesser PMF, Hanks SK (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-06-0456CrossRefPubMed

22.

Pablo MJ, Jesica DV, Yachuan Y, Iain M, Emma S, Ruth P, Norman JC, Margaret F, Marcos V (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genet. https://doi.org/10.1371/journal.pgen.1004262CrossRef

23.

Xianbo W, Jie W, Qi L, Rongsheng T, Jianli H, Xinwei Y, Yihua X, Wenjing W, Minghan S, Jianyou S (2022) Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. Biomed Pharmacother. https://doi.org/10.1016/j.biopha.2022.113116CrossRef

24.

Domoto T, Uehara M, Bolidong D, Minamoto T (2020) Glycogen synthase kinase 3beta in cancer biology and treatment. Cells. https://doi.org/10.3390/cells9061388CrossRefPubMedPubMedCentral

25.

Sulzmaier FJ, Christine J, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev. https://doi.org/10.1038/nrc3792CrossRef

26.

Li H, Gao Y, Ren C (2021) Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer. Discov Oncol 12:29. https://doi.org/10.1007/s12672-021-00425-6CrossRefPubMedPubMedCentral

27.

Chen H, Wang D, Liu Y (2016) SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway. Mol Med Rep 13:3613–3618. https://doi.org/10.3892/mmr.2016.4946CrossRefPubMed

28.

Hwang YP, Yun HJ, Choi JH, Han EH, Kim HG, Song GY, Kwon K-i, Jeong TC, Jeong HG (2011) Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 55:594–605. https://doi.org/10.1002/mnfr.201000292CrossRefPubMed

29.

Gehren AS, de Souza WF, Sousa-Squiavinato ACM, Ramos DAA, Pires BRB, Abdelhay ESFW, Morgado-Diaz JA (2023) Parthenolide inhibits proliferation and invasion, promotes apoptosis, and reverts the cell–cell adhesion loss through downregulation of NF-κB pathway TNF-α-activated in colorectal cancer cells. Cell Biol Int 47:1638–1649. https://doi.org/10.1002/cbin.12060CrossRefPubMed

30.

Sun L, Yuan W, Wen G, Yu B, Xu F, Gan X, Tang J, Zeng Q, Zhu L, Chen C, Zhang W (2020) Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway. Oncol Rep 44:1184–1193. https://doi.org/10.3892/or.2020.7649CrossRefPubMed

31.

Binte SH, Maria SJ, Shreen KZ, Ahsan HS, Ajmal K, Tabassum MM, Khurshidul Z, Ahmed A, Gollahon LS, Fazle H, Mizanoor RS (2022) Parthenolide reverses the epithelial to mesenchymal transition process in breast cancer by targeting TGFbeta1: in vitro and in silico studies. Life Sci. https://doi.org/10.1016/j.lfs.2022.120610CrossRef

32.

Sztiller-Sikorska M, Czyz M (2020) Parthenolide as cooperating agent for anti-cancer treatment of various malignancies. Pharmaceuticals. https://doi.org/10.3390/ph13080194CrossRefPubMedPubMedCentral

33.

Minghua L, Ying Y, Dajun L, Ye C, Yan L (2020) Parthenolide increases the sensitivity of gastric cancer cells to chemotherapy. J Trad Chin Med. https://doi.org/10.19852/j.cnki.jtcm.2020.06.002CrossRef

34.

Bartova E, Suchankova J, Legartova S, Malyskova B, Hornacek M, Skalnikova M, Masata M, Raska I, Kozubek S (2017) PCNA is recruited to irradiated chromatin in late S-phase and is most pronounced in G2 phase of the cell cycle. Protoplasma 254:2035–2043. https://doi.org/10.1007/s00709-017-1076-1CrossRefPubMed

35.

Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. https://doi.org/10.1083/jcb.123.3.513CrossRefPubMed

36.

Wu HJ, Hao M, Yeo SK, Guan JL (2020) FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. Oncogene 39:2539–2549. https://doi.org/10.1038/s41388-020-1162-2CrossRefPubMedPubMedCentral

37.

Zhao J, Guan JL (2009) Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28:35–49. https://doi.org/10.1007/s10555-008-9165-4CrossRefPubMed

38.

Fan X, Xiong H, Wei J, Gao X, Feng Y, Liu X, Zhang G, He Q-Y, Xu J, Liu L (2015) Cytoplasmic hnRNPK interacts with GSK3β and is essential for the osteoclast differentiation. Sci Report. https://doi.org/10.1038/srep17732CrossRef

39.

Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, Nakada M, Minamoto T (2016) Glycogen synthase kinase-3beta is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci 107:1363–1372. https://doi.org/10.1111/cas.13028CrossRefPubMedPubMedCentral

40.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O’Halloran TV, Giles FJ, Billadeau DD, Mazar AP (2017) Molecular pathways: revisiting glycogen synthase kinase-3beta as a target for the treatment of cancer. Clin Cancer Res 23:1891–1897. https://doi.org/10.1158/1078-0432.CCR-15-2240CrossRefPubMedPubMedCentral

41.

Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, Wang Y, Li W (2022) Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 15:94. https://doi.org/10.1186/s13045-022-01311-6CrossRefPubMedPubMedCentral

42.

Niu X, Chen J, Ma N, Huang R, Tao C, Dan Q, Fang Y (2022) Nuclear-targeted EGF receptor enhances proliferation and migration of human anaplastic thyroid cancer cells. Endokrynol Pol 73:803–811. https://doi.org/10.5603/EP.a2022.0048CrossRefPubMed

43.

Fu K, Zhang L, Liu R, Shi Q, Li X, Wang M (2020) MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway. World J Surg Oncol 18:115. https://doi.org/10.1186/s12957-020-01881-0CrossRefPubMedPubMedCentral

44.

Marzook H, Li DQ, Nair VS, Mudvari P, Reddy SD, Pakala SB, Santhoshkumar TR, Pillai MR, Kumar R (2012) Metastasis-associated protein 1 drives tumor cell migration and invasion through transcriptional repression of RING finger protein 144A. J Biol Chem 287:5615–5626. https://doi.org/10.1074/jbc.M111.314088CrossRefPubMed

45.

Zhang L, Zhou J, Qin X, Huang H, Nie C (2019) Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF-beta1-mediated PI3K and MAPK pathways. Oncol Rep 41:2975–2986. https://doi.org/10.3892/or.2019.7062CrossRefPubMed

Titel: Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway
verfasst von: Liru Huang
Fuhong Liu
Xukai Liu
Liyan Niu
Longhua Sun
Fang Fang
Kun Ma
Ping Hu
Publikationsdatum: 23.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2024
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-023-04621-9

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects

Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia

Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma

Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie